Secretory IgA impacts the microbiota density in the human nose.
IgA-seq
Mucosal immunology
Nasal antibodies
Nasal microbiota
Secretory IgA
Journal
Microbiome
ISSN: 2049-2618
Titre abrégé: Microbiome
Pays: England
ID NLM: 101615147
Informations de publication
Date de publication:
21 10 2023
21 10 2023
Historique:
received:
24
01
2023
accepted:
24
09
2023
medline:
2
11
2023
pubmed:
22
10
2023
entrez:
21
10
2023
Statut:
epublish
Résumé
Respiratory mucosal host defense relies on the production of secretory IgA (sIgA) antibodies, but we currently lack a fundamental understanding of how sIgA is induced by contact with microbes and how such immune responses may vary between humans. Defense of the nasal mucosal barrier through sIgA is critical to protect from infection and to maintain homeostasis of the microbiome, which influences respiratory disorders and hosts opportunistic pathogens. We applied IgA-seq analysis to nasal microbiota samples from male and female healthy volunteers, to identify which bacterial genera and species are targeted by sIgA on the level of the individual host. Furthermore, we used nasal sIgA from the same individuals in sIgA deposition experiments to validate the IgA-seq outcomes. We observed that the amount of sIgA secreted into the nasal mucosa by the host varied substantially and was negatively correlated with the bacterial density, suggesting that nasal sIgA limits the overall bacterial capacity to colonize. The interaction between mucosal sIgA antibodies and the nasal microbiota was highly individual with no obvious differences between potentially invasive and non-invasive bacterial species. Importantly, we could show that for the clinically relevant opportunistic pathogen and frequent nasal resident Staphylococcus aureus, sIgA reactivity was in part the result of epitope-independent interaction of sIgA with the antibody-binding protein SpA through binding of sIgA Fab regions. This study thereby offers a first comprehensive insight into the targeting of the nasal microbiota by sIgA antibodies. It thereby helps to better understand the shaping and homeostasis of the nasal microbiome by the host and may guide the development of effective mucosal vaccines against bacterial pathogens. Video Abstract.
Sections du résumé
BACKGROUND
Respiratory mucosal host defense relies on the production of secretory IgA (sIgA) antibodies, but we currently lack a fundamental understanding of how sIgA is induced by contact with microbes and how such immune responses may vary between humans. Defense of the nasal mucosal barrier through sIgA is critical to protect from infection and to maintain homeostasis of the microbiome, which influences respiratory disorders and hosts opportunistic pathogens.
METHODS
We applied IgA-seq analysis to nasal microbiota samples from male and female healthy volunteers, to identify which bacterial genera and species are targeted by sIgA on the level of the individual host. Furthermore, we used nasal sIgA from the same individuals in sIgA deposition experiments to validate the IgA-seq outcomes.
CONCLUSIONS
We observed that the amount of sIgA secreted into the nasal mucosa by the host varied substantially and was negatively correlated with the bacterial density, suggesting that nasal sIgA limits the overall bacterial capacity to colonize. The interaction between mucosal sIgA antibodies and the nasal microbiota was highly individual with no obvious differences between potentially invasive and non-invasive bacterial species. Importantly, we could show that for the clinically relevant opportunistic pathogen and frequent nasal resident Staphylococcus aureus, sIgA reactivity was in part the result of epitope-independent interaction of sIgA with the antibody-binding protein SpA through binding of sIgA Fab regions. This study thereby offers a first comprehensive insight into the targeting of the nasal microbiota by sIgA antibodies. It thereby helps to better understand the shaping and homeostasis of the nasal microbiome by the host and may guide the development of effective mucosal vaccines against bacterial pathogens. Video Abstract.
Identifiants
pubmed: 37865781
doi: 10.1186/s40168-023-01675-y
pii: 10.1186/s40168-023-01675-y
pmc: PMC10589987
doi:
Substances chimiques
Immunoglobulin A, Secretory
0
Types de publication
Video-Audio Media
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
233Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
J Infect Dis. 2010 May 1;201(9):1414-21
pubmed: 20307206
Front Immunol. 2013 Aug 06;4:222
pubmed: 23964273
Mol Microbiol. 2014 Oct;94(2):403-17
pubmed: 25164331
J Allergy Clin Immunol. 2022 Jul;150(1):1-11
pubmed: 35569567
PLoS Pathog. 2013;9(12):e1003816
pubmed: 24348255
Acta Otolaryngol. 1976 Sep-Oct;82(3-4):216-8
pubmed: 983678
Sci Transl Med. 2015 Feb 25;7(276):276ra24
pubmed: 25717097
Lancet Infect Dis. 2005 Dec;5(12):751-62
pubmed: 16310147
Cell. 2014 Aug 28;158(5):1000-1010
pubmed: 25171403
PLoS One. 2010 Apr 06;5(4):e10040
pubmed: 20386721
Microbiome. 2021 Jan 30;9(1):33
pubmed: 33516266
J Clin Immunol. 2013 May;33(4):742-7
pubmed: 23389234
PLoS One. 2020 Apr 30;15(4):e0232456
pubmed: 32353071
J Clin Microbiol. 2017 Nov;55(11):3283-3291
pubmed: 28904182
Sci Immunol. 2022 Oct 28;7(76):eadd4853
pubmed: 35857583
Mol Immunol. 2008 Mar;45(6):1600-11
pubmed: 18061675
Nat Methods. 2016 Jul;13(7):581-3
pubmed: 27214047
Cell Host Microbe. 2016 Apr 13;19(4):550-9
pubmed: 27053168
PLoS One. 2013 Apr 22;8(4):e61217
pubmed: 23630581
Front Microbiol. 2021 Feb 10;12:613109
pubmed: 33643241
Front Cell Infect Microbiol. 2011 Sep 28;1:5
pubmed: 22919571
mBio. 2012 Mar 20;3(2):
pubmed: 22434850
J Microbiol Methods. 2000 Jul;41(2):135-43
pubmed: 10889310
PLoS Pathog. 2014 Jan;10(1):e1003862
pubmed: 24453967
PLoS Pathog. 2012;8(11):e1003033
pubmed: 23209408
mSystems. 2023 Jun 29;8(3):e0075722
pubmed: 37278524
Environ Microbiol. 2016 Jul;18(7):2130-42
pubmed: 25923378
mSystems. 2018 Dec 4;3(6):
pubmed: 30534599
Sci Rep. 2016 Aug 03;6:30964
pubmed: 27485391
Sci Transl Med. 2018 May 2;10(439):
pubmed: 29720448
Science. 2018 May 18;360(6390):795-800
pubmed: 29724905
Immunity. 2015 Sep 15;43(3):541-53
pubmed: 26320660
Immunology. 2020 Jan;159(1):52-62
pubmed: 31777063
Infection. 2005 Feb;33(1):3-8
pubmed: 15750752
Clin Diagn Lab Immunol. 2000 Jan;7(1):31-9
pubmed: 10618273
Auris Nasus Larynx. 2009 Jun;36(3):300-4
pubmed: 19013037
Microbiology (Reading). 1998 Apr;144 ( Pt 4):985-991
pubmed: 9579072
J Immunol. 2009 Oct 1;183(7):4583-92
pubmed: 19752232
Proc Natl Acad Sci U S A. 2000 May 9;97(10):5399-404
pubmed: 10805799
Microbiome. 2020 May 15;8(1):65
pubmed: 32414415
J Allergy Clin Immunol. 2015 Mar;135(3):811-3.e5
pubmed: 25533526
Front Microbiol. 2020 Jan 29;11:65
pubmed: 32117109
Nature. 2016 Jul 27;535(7613):511-6
pubmed: 27466123
Sci Adv. 2015 Jun 05;1(5):e1400216
pubmed: 26601194
J Allergy Clin Immunol. 2017 Feb;139(2):492-500.e8
pubmed: 27315768
Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):15051-6
pubmed: 17848512
Nat Rev Immunol. 2022 Apr;22(4):236-250
pubmed: 34312520
Nat Rev Microbiol. 2017 Oct 12;15(11):675-687
pubmed: 29021598
Nat Biotechnol. 2019 Aug;37(8):852-857
pubmed: 31341288
BMC Microbiol. 2012 Apr 17;12:56
pubmed: 22510143
mBio. 2013 Aug 27;4(5):e00575-13
pubmed: 23982075
mBio. 2015 May 26;6(3):e00308-15
pubmed: 26015493